SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
07 juil. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
29 juin 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak
18 juin 2015 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Present at the JMP Securities Life Sciences Conference
16 juin 2015 11h40 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
CORRECTING and REPLACING - SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results
14 mai 2015 08h53 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SteadyMed Ltd. (Nasdaq:STDY), please note that in the first paragraph under the First...
SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results
14 mai 2015 07h39 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension
07 mai 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug...
SteadyMed Granted Additional U.S. Patent With Patent Term Extension
22 avr. 2015 07h00 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced the issuance of a new patent from the United States Patent and...
SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer
08 avr. 2015 07h30 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive...
SteadyMed Announces Closing of Initial Public Offering
25 mars 2015 14h26 HE
|
SteadyMed Therapeutics
SAN RAMON, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd., a specialty pharmaceutical company, today announced the closing of its initial public offering of 4,700,000 ordinary shares at a...